We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » EMA May Allow pCR as Endpoint In Neoadjuvant Breast Cancer Trials
EMA May Allow pCR as Endpoint In Neoadjuvant Breast Cancer Trials
May 8, 2014
The European Medicines Agency is considering new trial designs using pathologic complete response, or pCR, as an endpoint in neoadjuvant breast cancer studies for patients with aggressive, early-stage breast cancer.